The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
U. Emmenegger
No relevant relationships to disclose
S. R. Berry
No relevant relationships to disclose
C. M. Booth
No relevant relationships to disclose
S. S. Sridhar
No relevant relationships to disclose
E. Winquist
No relevant relationships to disclose
N. Bandali
No relevant relationships to disclose
A. Chow
No relevant relationships to disclose
R. Kerbel
Honoraria - Wyeth
Y. Ko
No relevant relationships to disclose